|
|
Blood, 15 July 2006, Vol. 108, No. 2, pp. 432-440.
Prepublished online as a Blood First Edition Paper on March 16, 2006; DOI 10.1182/blood-2005-06-2383.
 Previous Article | Next Article 
Submitted June 14, 2005
Accepted February 27, 2006
The chemokine CXCL13 is a key molecule in autoimmune Myasthenia Gravis
Amel Meraouna, Geraldine Cizeron-Clairac, Rozen Le Panse, Jacky Bismuth, Frederique Truffault, Chantal Tallaksen, and Sonia Berrih-Aknin*
CNRS-UMR 8162, IPSC, Universite Paris XI, Hopital Marie Lannelongue, Le Plessis Robinson, France
Department of Neurology, Ulleval University Hospital, Oslo, Norway
* Corresponding author; email: sonia.berrih{at}ccml.u-psud.fr.
Myasthenia Gravis (MG) is associated with ectopic germinal centres in the thymus. Thymectomy and glucocorticoids are the main treatments but they induce operative risks and side effects, respectively. The aim of this study was to propose new therapies more efficient for MG. We hypothesized that molecules dysregulated in MG thymus and normalized by glucocorticoids may play a key role in thymic pathogenesis. Using gene chip analysis, we identified 88 genes complying with these criteria, the most remarkable being the B cell chemoattractant (CXCL13). Its expression was increased in thymus and sera of glucocorticoid untreated patients and decreased in response to treatment in correlation with clinical improvement. Normal B cells were actively chemoattracted by thymic extracts from glucocorticoid untreated patients, an effect inhibited by anti-CXCL13 antibodies. In the thymus, CXCL13 was preferentially produced by epithelial cells and overproduced by epithelial cells from MG patients. Altogether, our results suggest that a high CXCL13 production by epithelial cells could be responsible for germinal centre formation in MG thymus. Furthermore, they show that this gene is a main target of corticotherapy. Thus, new therapies targeting CXCL13 could be of interest for MG and other autoimmune diseases characterized by ectopic germinal centre formation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Burkle, M. Niedermeier, A. Schmitt-Graff, W. G. Wierda, M. J. Keating, and J. A. Burger
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia
Blood,
November 1, 2007;
110(9):
3316 - 3325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I. Leite, M. Jones, P. Strobel, A. Marx, R. Gold, E. Niks, J. J.G.M. Verschuuren, S. Berrih-Aknin, F. Scaravilli, A. Canelhas, et al.
Myasthenia Gravis Thymus: Complement Vulnerability of Epithelial and Myoid Cells, Complement Attack on Them, and Correlations with Autoantibody Status
Am. J. Pathol.,
September 1, 2007;
171(3):
893 - 905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Le Panse, G. Cizeron-Clairac, J. Bismuth, and S. Berrih-Aknin
Microarrays Reveal Distinct Gene Signatures in the Thymus of Seropositive and Seronegative Myasthenia Gravis Patients and the Role of CC Chemokine Ligand 21 in Thymic Hyperplasia
J. Immunol.,
December 1, 2006;
177(11):
7868 - 7879.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
